Form 4: Cellectar Biosciences Director Acquires Stock Options
SEC Form 4 Filing
Asher Chanan-Khan, a director of Cellectar Biosciences, acquired stock options for 60,000 shares on February 14, 2025.
Summary
- On February 14, 2025, Asher Chanan-Khan, a director of Cellectar Biosciences, acquired stock options to purchase 60,000 shares of common stock.
- The exercise price of the options is $0.29 per share.
- The options vest fully on February 14, 2026, contingent upon continued service.
- The options expire on February 14, 2035.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider ownership can be a positive signal, this is just an option grant, not an open market purchase.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could potentially increase shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of transaction: Asher Chanan-Khan acquired stock options. |
| 02/14/2026 | Vesting date for the stock options. |
| 02/14/2035 | Expiration date for the stock options. |
| 02/18/2025 | Date of Form 4 filing. |
Keywords
stock options, director, Cellectar Biosciences, CLRB, beneficial ownership, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.